COBRA: TOL+ INTERFERON-alpha COMBINED WITH VEMURAFENIB (BRAF-mutation positive patients) OR TOL + INTERFERON- alpha (BRAF-mutation negative patients) FOR PATIENTS WITH ADVANCED MELANOMA AS 1st CHEMOTHERAPY-BASED TREATMENT

Trial Profile

COBRA: TOL+ INTERFERON-alpha COMBINED WITH VEMURAFENIB (BRAF-mutation positive patients) OR TOL + INTERFERON- alpha (BRAF-mutation negative patients) FOR PATIENTS WITH ADVANCED MELANOMA AS 1st CHEMOTHERAPY-BASED TREATMENT

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Aug 2013

At a glance

  • Drugs Vemurafenib (Primary) ; Antineoplastics; Interferon alpha
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Acronyms COBRA
  • Most Recent Events

    • 20 Aug 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top